Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1973 2
1974 1
1975 1
1976 2
1977 1
1984 1
1988 1
1991 1
1992 1
1993 1
1996 2
1997 1
2000 3
2001 4
2002 5
2003 6
2004 2
2006 2
2008 1
2012 1
2014 2
2015 5
2016 3
2017 4
2018 8
2019 1
2020 4
2021 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Fernandez AP, Dauden E, Gerdes S, Lebwohl MG, Menter MA, Leonardi CL, Gooderham M, Gebauer K, Tada Y, Lacour JP, Bianchi L, Egeberg A, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Mehta NN. Fernandez AP, et al. Among authors: menter ma. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1774-1783. doi: 10.1111/jdv.18167. Epub 2022 Jun 25. J Eur Acad Dermatol Venereol. 2022. PMID: 35460287 Free PMC article. Clinical Trial.
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Thaçi D, et al. Among authors: menter ma. Dermatol Ther (Heidelb). 2022 Feb;12(2):495-510. doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13. Dermatol Ther (Heidelb). 2022. PMID: 35025062 Free PMC article.
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, Jehl V, Marfo K, Primatesta P, Shete A, Trivedi V, Mease PJ. Lebwohl M, et al. Among authors: menter ma. Br J Dermatol. 2021 Nov;185(5):935-944. doi: 10.1111/bjd.20136. Epub 2021 Jun 8. Br J Dermatol. 2021. PMID: 33829482 Clinical Trial.
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter MA. Lebwohl MG, et al. Among authors: menter ma. J Am Acad Dermatol. 2021 Feb;84(2):398-407. doi: 10.1016/j.jaad.2020.09.047. Epub 2020 Sep 19. J Am Acad Dermatol. 2021. PMID: 32961255 Free article. Clinical Trial.
IL-17 inhibitors for psoriasis.
Paek SY, Frieder J, Kivelevitch D, Menter MA. Paek SY, et al. Among authors: menter ma. Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051. Semin Cutan Med Surg. 2018. PMID: 30215631 Review.
69 results